FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
· · · · · · · · · · · · · · · · · · ·		

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Smither John W				2. Issuer Name and Ticker or Trading Symbol <u>eFFECTOR Therapeutics</u> , <u>Inc.</u> [EFTR]								ck all applic Directo	or		rson(s) to Issuer			
(Last)	`	irst) HERAPEUTICS	(Middle)		3. Date of Earliest Transaction (Month 10/06/2021					Day/Year)				Officer below)	(give title		Other (s below)	specify
11120 ROSELLE ST SUITE A				4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)							
(Street) SAN DII	EGO C.	A	92121								X	,						
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,		Code (Ir	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)				4 and Securition Benefici		es For ially (D) Following (I) (orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)	Pı	rice		action(s)			(111341. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, General Or Exercise (Month/Day/Year) if any			′ Co	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and of Securiti Underlying Derivative (Instr. 3 an			ies g Secu		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	i illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Co	de V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amo or Num of Shar	ber					
Stock Option (Right to Buy)	\$11.36	10/06/2021		A	A	40,000		(1)	1	0/05/2031	Common Stock	40,0	000	\$0.00	40,000)	D	

Explanation of Responses:

1. The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Reporting Person's continued service with the Issuer through each vesting date.

Remarks:

/s/ Michael Byrnes, Attorneyin-Fact for John W. Smither

10/08/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.